



All correspondence should be addressed to the Director General

LET\_LSE\_PMS\_0013/08/25  
In reply, please quote

# ZAMBIA MEDICINES REGULATORY AUTHORITY

## PUBLIC NOTICE

Date: 22<sup>nd</sup> August 2025

To: General Public

### URGENT PUBLIC ALERT:

#### RECALL OF FUROSEMIDE TABLETS 40MG BP MANUFACTURED BY KAUSIKH THERAPEUTICS LTD INDIA

FOR IMMEDIATE RELEASE – The Zambia Medicines Regulatory Authority (ZAMRA) is a statutory body established under an Act of Parliament, the Medicines and Allied Substances Act No. 3 of 2013 of the Laws of Zambia. The main mandate of ZAMRA is to ensure the quality, safety and efficacy of medicines and allied substances for human and animal health protection.

On this background, the Authority wishes to notify all healthcare professionals, health facilities, pharmaceutical outlets and members of the public that it has instructed Sweet Pharmaceuticals, Limited to urgently **RECALL** the above-stated product due to failure to meet its Disintegration specifications. This implies that the product takes longer to break down into smaller particles required for drug absorption.

Product details:

S/N	Name of Product	Manufacturer	Batch No.	Expiry Date	CoA Number	Test Results
1.	Furosemide Tablets 40 mg	Kausikh Therapeutics (P)Limited, India	KE23390	09/2026	Z/25/280-1 & Z/25/279-1	Non-compliant

### RISK

Furosemide is used alone or together with other medicines to treat fluid retention in the body (oedema) and high blood pressure (hypertension). Using a medicine that takes longer than the standard time to break down into smaller particles may lead to slow absorption of the required amount of the medicine and may affect the desired treatment outcome.

If you are in possession of this batch (**KE23390**), please return it to your healthcare provider who should replace it with another batch or brand. Pharmaceutical outlets and health facilities in possession of the affected batch should quarantine the product and return it to their supplier(s), for collection and disposal by the importer.

Should you need further clarification, please do not hesitate to contact our Secretariat.

Makomani Siyanga (Mr)  
DIRECTOR-GENERAL

#### Head Office

Plot No: 2350/M  
Off Kenneth Kaunda International Airport Road.  
P.O. Box 31890, Lusaka, ZAMBIA  
Tel: +260 211 432 350 /432 351  
E-mail: [pharmacy@zamra.co.zm](mailto:pharmacy@zamra.co.zm)

Report Adverse Reactions to:  
Pharmacovigilance Unit, Lusaka  
Tel: +260 211 432 356

E-mail: [npvu@zamra.co.zm](mailto:npvu@zamra.co.zm)  
Website: [www.zamra.co.zm](http://www.zamra.co.zm)